Best Peptides for Weight Loss & Fat Loss
The peptides most studied for weight loss are GLP-1 receptor agonists like semaglutide, tirzepatide, and retatrutide, which reduce appetite and improve metabolic markers in clinical trials. Other research compounds studied for fat metabolism include AOD-9604, 5-Amino-1MQ, tesofensine, and MOTS-c.
Weight-loss peptides fall into two broad groups. The GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide and related molecules) are the most clinically validated — large human trials show meaningful appetite reduction and weight change. A second group of metabolic and lipolytic compounds (AOD-9604, 5-Amino-1MQ, tesofensine, MOTS-c) target fat metabolism through different mechanisms and rest on a thinner evidence base. Below, each is graded so you can tell the well-proven from the preliminary.
⚠ Research & educational use only — not medical adviceMost-studied compounds for weight loss & fat loss
Each links to a full research protocol with reconstitution steps, research dose ranges reported in the literature, and an honest evidence grade. Ranked roughly by depth of supporting research.
Semaglutide
GLP-1 agonistA GLP-1 receptor agonist with extensive human trial data for appetite suppression and weight reduction — among the most studied molecules in this category.
View protocol →Tirzepatide
GIP/GLP-1A dual GIP/GLP-1 agonist studied in large trials for weight and metabolic outcomes, often producing larger changes than single-agonist molecules.
View protocol →Retatrutide
Triple agonistAn investigational triple GIP/GLP-1/glucagon agonist showing strong weight-related signals in early trials — newer, with a growing evidence base.
View protocol →Cagrilintide
Amylin analogA long-acting amylin analog studied alongside GLP-1 agonists for additive appetite and weight effects.
View protocol →Survodutide
GLP-1/glucagonA dual GLP-1/glucagon agonist investigated for weight and metabolic-liver outcomes.
View protocol →Orforglipron
Oral GLP-1A non-peptide oral GLP-1 agonist in clinical development — notable for oral dosing.
View protocol →AOD-9604
Lipolytic fragmentA modified fragment of growth hormone studied for fat metabolism without the full systemic effects of GH; human evidence is limited.
View protocol →5-Amino-1MQ
NNMT inhibitorAn oral NNMT inhibitor researched for raising cellular NAD+ and promoting fat-cell energy expenditure; mostly preclinical.
View protocol →Tesofensine
Triple reuptakeA centrally-acting appetite-suppressant studied in human weight-loss trials with notable but preliminary results.
View protocol →MOTS-c
MitochondrialA mitochondrial-derived peptide studied for metabolic regulation and exercise-like effects; early-stage evidence.
View protocol →Sourcing these compounds for research
Researchers studying the molecules above source cGMP-tested material from our official sponsor, LiveWell Peptides. All compounds are sold strictly for laboratory research use.
Source at LiveWell Peptides →Preferred vendor. For research use only. Not for human consumption. Not medical advice.
Plan your research
Free tools to take any compound above from vial to a documented protocol.
Frequently asked questions
- Which weight-loss peptide has the strongest evidence?
- The GLP-1 receptor agonists — semaglutide and tirzepatide — have by far the largest body of human clinical-trial data. The other compounds on this page are earlier-stage and rest mainly on small or preclinical studies.
- Can these peptides be stacked?
- Some researchers study combinations (for example a GLP-1 agonist with an amylin analog), but stacking increases complexity and risk. Use the Stack Checker and consult a licensed provider before combining anything.
- Are these peptides legal and FDA-approved?
- Most research peptides discussed here are not FDA-approved for human use and are sold strictly for laboratory research purposes. A few molecules (such as certain GLP-1 receptor agonists) exist in approved prescription forms, but the research-grade material referenced on this site is not the same as a prescription product. Always consult a licensed healthcare provider before making any health decision.
- How strong is the research behind these?
- It varies by compound. Some — like the GLP-1 agonists — have large human clinical trials; others (such as BPC-157 or Epithalon) rest mainly on animal and in-vitro data with limited human studies. Each protocol page on this site grades the evidence so you can see exactly what is well-supported versus preliminary.